{"id":4906,"date":"2025-06-06T07:37:32","date_gmt":"2025-06-06T06:37:32","guid":{"rendered":"https:\/\/cbmeds.in\/?post_type=product&#038;p=4906"},"modified":"2025-06-06T07:41:33","modified_gmt":"2025-06-06T06:41:33","slug":"4906","status":"publish","type":"product","link":"https:\/\/cbmeds.in\/?product=4906","title":{"rendered":"BALVERSA 3MG \/4MG \/5MG TABLET (ERDAFITINIB)"},"content":{"rendered":"<p data-start=\"0\" data-end=\"112\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"><strong data-start=\"0\" data-end=\"27\" data-is-only-node=\"\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Balversa (Erdafitinib)<\/strong> is an oral targeted therapy approved for the treatment of adults with <strong data-start=\"98\" data-end=\"159\">locally advanced or metastatic urothelial carcinoma (mUC)<\/strong> <\/span><\/p>\n<p data-start=\"0\" data-end=\"112\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 harboring susceptible <strong data-start=\"182\" data-end=\"211\">FGFR3 genetic alterations<\/strong>, particularly in cases where the disease has progressed following at least one prior systemic therapy.<\/span><\/p>\n<hr data-start=\"114\" data-end=\"117\" \/>\n<h3 data-start=\"119\" data-end=\"158\">\ud83e\uddec <strong data-start=\"126\" data-end=\"158\">Composition &amp; Classification<\/strong><\/h3>\n<ul data-start=\"160\" data-end=\"430\">\n<li data-start=\"160\" data-end=\"217\">\n<p data-start=\"162\" data-end=\"217\"><strong data-start=\"162\" data-end=\"178\">Generic Name<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Erdafitinib<\/span><\/p>\n<\/li>\n<li data-start=\"218\" data-end=\"273\">\n<p data-start=\"220\" data-end=\"273\"><strong data-start=\"220\" data-end=\"234\">Brand Name<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Balversa<\/span><\/p>\n<\/li>\n<li data-start=\"274\" data-end=\"331\">\n<p data-start=\"276\" data-end=\"331\"><strong data-start=\"276\" data-end=\"290\">Drug Class<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Fibroblast Growth Factor Receptor (FGFR) kinase inhibitor<\/span><\/p>\n<\/li>\n<li data-start=\"332\" data-end=\"430\">\n<p data-start=\"334\" data-end=\"430\"><strong data-start=\"334\" data-end=\"350\">Manufacturer<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Janssen Pharmaceuticals<\/span><\/p>\n<\/li>\n<\/ul>\n<hr data-start=\"432\" data-end=\"435\" \/>\n<h3 data-start=\"437\" data-end=\"459\">\ud83d\udccb <strong data-start=\"444\" data-end=\"459\">Indications<\/strong><\/h3>\n<p>&nbsp;<\/p>\n<p data-start=\"461\" data-end=\"539\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Balversa is indicated for the treatment of adult patients with:<\/span><\/p>\n<p data-start=\"461\" data-end=\"539\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\" style=\"font-size: 16px;\"><strong data-start=\"0\" data-end=\"61\" data-is-only-node=\"\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Locally advanced or metastatic urothelial carcinoma (mUC)<\/strong> with susceptible <strong data-start=\"79\" data-end=\"108\">FGFR3 genetic alterations<\/strong>, whose disease has progressed on<\/span><\/p>\n<p data-start=\"461\" data-end=\"539\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\" style=\"font-size: 16px;\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 or after at least one line of prior systemic therapy. <\/span><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Patients should be selected for therapy based on the presence of susceptible FGFR3 genetic alterations, <\/span><\/p>\n<p data-start=\"461\" data-end=\"539\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 as detected by an FDA-approved companion diagnostic test.<\/span><\/p>\n<hr data-start=\"783\" data-end=\"786\" \/>\n<h3 data-start=\"788\" data-end=\"822\">\ud83d\udc8a <strong data-start=\"795\" data-end=\"822\">Dosage &amp; Administration<\/strong><\/h3>\n<p>&nbsp;<\/p>\n<ul data-start=\"824\" data-end=\"1147\">\n<li data-start=\"824\" data-end=\"884\">\n<p data-start=\"826\" data-end=\"884\"><strong data-start=\"826\" data-end=\"843\">Starting Dose<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">8 mg orally once daily (two 4 mg tablets)<\/span><\/p>\n<\/li>\n<li data-start=\"885\" data-end=\"947\">\n<p data-start=\"887\" data-end=\"947\"><strong data-start=\"887\" data-end=\"906\">Dose Adjustment<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Increase to 9 mg once daily (three 3 mg tablets) based on serum phosphate levels and tolerability, assessed between days 14 and 21 of treatment.<\/span><\/p>\n<\/li>\n<li data-start=\"948\" data-end=\"1009\">\n<p data-start=\"950\" data-end=\"1009\"><strong data-start=\"950\" data-end=\"968\">Administration<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Take with or without food; swallow tablets whole.<\/span><\/p>\n<\/li>\n<li data-start=\"1010\" data-end=\"1147\">\n<p data-start=\"1012\" data-end=\"1147\"><strong data-start=\"1012\" data-end=\"1027\">Missed Dose<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">If a dose is missed, it can be taken as soon as possible on the same day. Resume the regular dosing schedule the next day. Do not take extra tablets to make up for the missed dose.<\/span><\/p>\n<\/li>\n<\/ul>\n<hr data-start=\"1149\" data-end=\"1152\" \/>\n<h3 data-start=\"1154\" data-end=\"1187\">\u26a0\ufe0f <strong data-start=\"1161\" data-end=\"1187\">Warnings &amp; Precautions<\/strong><\/h3>\n<p>&nbsp;<\/p>\n<ul data-start=\"1189\" data-end=\"1647\">\n<li data-start=\"1189\" data-end=\"1289\">\n<p data-start=\"1191\" data-end=\"1289\"><strong data-start=\"1191\" data-end=\"1208\">Eye Disorders<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Balversa may cause central serous retinopathy\/retinal pigment epithelial detachment, leading to visual field defects. Regular ophthalmologic evaluations are recommended.<\/span><\/p>\n<\/li>\n<li data-start=\"1290\" data-end=\"1394\">\n<p data-start=\"1292\" data-end=\"1394\"><strong data-start=\"1292\" data-end=\"1313\">Hyperphosphatemia<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">High phosphate levels in the blood are common and can be serious. Monitor serum phosphate levels regularly and manage as needed.<\/span><\/p>\n<\/li>\n<li data-start=\"1395\" data-end=\"1503\">\n<p data-start=\"1397\" data-end=\"1503\"><strong data-start=\"1397\" data-end=\"1422\">Embryo-Fetal Toxicity<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Balversa can cause fetal harm. Advise females of reproductive potential to use effective contraception during treatment and for one month after the final dose.<\/span><\/p>\n<\/li>\n<li data-start=\"1504\" data-end=\"1647\">\n<p data-start=\"1506\" data-end=\"1647\"><strong data-start=\"1506\" data-end=\"1527\">Drug Interactions<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Avoid concomitant use with strong CYP3A4 inducers. Monitor for adverse reactions when coadministered with moderate CYP2C9 or strong CYP3A4 inhibitors.<\/span><\/p>\n<\/li>\n<\/ul>\n<hr data-start=\"1649\" data-end=\"1652\" \/>\n<h3 data-start=\"1654\" data-end=\"1677\">\u26a0\ufe0f <strong data-start=\"1661\" data-end=\"1677\">Side Effects<\/strong><\/h3>\n<p>&nbsp;<\/p>\n<p data-start=\"1679\" data-end=\"1703\"><strong data-start=\"1679\" data-end=\"1702\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Common Side Effects<\/strong>:<\/p>\n<ul data-start=\"1705\" data-end=\"2335\">\n<li data-start=\"1705\" data-end=\"1746\">\n<p data-start=\"1707\" data-end=\"1746\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Nail disorders (e.g., separation from the nail bed)<\/span><\/p>\n<\/li>\n<li data-start=\"1747\" data-end=\"1788\">\n<p data-start=\"1749\" data-end=\"1788\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Mouth sores<\/span><\/p>\n<\/li>\n<li data-start=\"1789\" data-end=\"1830\">\n<p data-start=\"1791\" data-end=\"1830\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Diarrhea<\/span><\/p>\n<\/li>\n<li data-start=\"1831\" data-end=\"1872\">\n<p data-start=\"1833\" data-end=\"1872\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Increased creatinine levels<\/span><\/p>\n<\/li>\n<li data-start=\"1873\" data-end=\"1914\">\n<p data-start=\"1875\" data-end=\"1914\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Altered liver function tests<\/span><\/p>\n<\/li>\n<li data-start=\"1915\" data-end=\"1956\">\n<p data-start=\"1917\" data-end=\"1956\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Anemia<\/span><\/p>\n<\/li>\n<li data-start=\"1957\" data-end=\"1998\">\n<p data-start=\"1959\" data-end=\"1998\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Fatigue<\/span><\/p>\n<\/li>\n<li data-start=\"1999\" data-end=\"2040\">\n<p data-start=\"2001\" data-end=\"2040\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Dry mouth and skin<\/span><\/p>\n<\/li>\n<li data-start=\"2041\" data-end=\"2082\">\n<p data-start=\"2043\" data-end=\"2082\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Decreased appetite<\/span><\/p>\n<\/li>\n<li data-start=\"2083\" data-end=\"2124\">\n<p data-start=\"2085\" data-end=\"2124\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Changes in taste<\/span><\/p>\n<\/li>\n<li data-start=\"2125\" data-end=\"2166\">\n<p data-start=\"2127\" data-end=\"2166\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Constipation<\/span><\/p>\n<\/li>\n<li data-start=\"2167\" data-end=\"2208\">\n<p data-start=\"2169\" data-end=\"2208\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Hair loss<\/span><\/p>\n<\/li>\n<li data-start=\"2209\" data-end=\"2335\">\n<p data-start=\"2211\" data-end=\"2335\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Redness, swelling, or tenderness on hands and feet (hand-foot syndrome)<\/span><\/p>\n<\/li>\n<\/ul>\n<p data-start=\"2337\" data-end=\"2362\"><strong data-start=\"2337\" data-end=\"2361\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Serious Side Effects<\/strong>:<\/p>\n<ul data-start=\"2364\" data-end=\"2578\">\n<li data-start=\"2364\" data-end=\"2407\">\n<p data-start=\"2366\" data-end=\"2407\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Eye problems, including blurred vision, vision loss, or other visual changes<\/span><\/p>\n<\/li>\n<li data-start=\"2408\" data-end=\"2451\">\n<p data-start=\"2410\" data-end=\"2451\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">High phosphate levels leading to muscle cramps, numbness, or tingling around the mouth<\/span><\/p>\n<\/li>\n<li data-start=\"2452\" data-end=\"2578\">\n<p data-start=\"2454\" data-end=\"2578\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Skin reactions, including painful skin lesions<\/span><\/p>\n<\/li>\n<\/ul>\n<hr data-start=\"2580\" data-end=\"2583\" \/>\n<h3 data-start=\"2585\" data-end=\"2605\">\u2705 <strong data-start=\"2591\" data-end=\"2605\">Conclusion<\/strong><\/h3>\n<p>&nbsp;<\/p>\n<p data-start=\"2607\" data-end=\"2773\"><span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Balversa (Erdafitinib) offers a targeted treatment option for patients with advanced urothelial carcinoma harboring FGFR3 genetic alterations, especially after progression on prior therapies.<\/span> <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Due to potential serious side effects, including eye disorders and hyperphosphatemia, careful patient selection and regular monitoring are essential.<\/span> <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Patients should discuss the risks and benefits of Balversa with their healthcare provider to determine its suitability for their treatment plan <\/span>For more detailed information, please refer to the <a class=\"cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"2826\" data-end=\"2964\">official information<\/a> or consult your healthcare provider.<\/p>\n","protected":false},"excerpt":{"rendered":"<h3 data-start=\"75\" data-end=\"97\">\ud83d\udccc <strong data-start=\"82\" data-end=\"97\">Key Details<\/strong><\/h3>\n<ul data-start=\"99\" data-end=\"541\">\n<li data-start=\"99\" data-end=\"154\">\n<p data-start=\"101\" data-end=\"154\"><strong data-start=\"101\" data-end=\"115\">Brand Name<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Balversa<\/span><\/p>\n<\/li>\n<li data-start=\"155\" data-end=\"219\">\n<p data-start=\"157\" data-end=\"219\"><strong data-start=\"157\" data-end=\"180\">Generic Name (Salt)<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Erdafitinib<\/span><\/p>\n<\/li>\n<li data-start=\"220\" data-end=\"277\">\n<p data-start=\"222\" data-end=\"277\"><strong data-start=\"222\" data-end=\"238\">Manufacturer<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Janssen Pharmaceuticals, Inc.<\/span><\/p>\n<\/li>\n<li data-start=\"278\" data-end=\"336\">\n<p data-start=\"280\" data-end=\"336\"><strong data-start=\"280\" data-end=\"295\">Formulation<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Oral tablets<\/span><\/p>\n<\/li>\n<li data-start=\"337\" data-end=\"403\">\n<p data-start=\"339\" data-end=\"403\"><strong data-start=\"339\" data-end=\"362\">Available Strengths<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">3 mg, 4 mg, and 5 mg<\/span><\/p>\n<\/li>\n<li data-start=\"404\" data-end=\"541\">\n<p data-start=\"406\" data-end=\"541\"><strong data-start=\"406\" data-end=\"420\">Indication<\/strong>: <span class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\">Treatment of adults with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 genetic alterations, whose disease has progressed on or after at least one line of prior systemic therapy<\/span><\/p>\n<\/li>\n<\/ul>\n","protected":false},"featured_media":4907,"comment_status":"open","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[86],"product_tag":[],"class_list":{"0":"post-4906","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-urothelial-carcinoma","7":"desktop-align-left","8":"tablet-align-left","9":"mobile-align-left","11":"first","12":"instock","13":"shipping-taxable","14":"product-type-simple"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BALVERSA 3MG \/4MG \/5MG TABLET (ERDAFITINIB) - Curiance Biotech<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cbmeds.in\/?product=4906\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BALVERSA 3MG \/4MG \/5MG TABLET (ERDAFITINIB) - Curiance Biotech\" \/>\n<meta property=\"og:description\" content=\"\ud83d\udccc Key Details    Brand Name: Balversa    Generic Name (Salt): Erdafitinib    Manufacturer: Janssen Pharmaceuticals, Inc.    Formulation: Oral tablets    Available Strengths: 3 mg, 4 mg, and 5 mg    Indication: Treatment of adults with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 genetic alterations, whose disease has progressed on or after at least one line of prior systemic therapy\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cbmeds.in\/?product=4906\" \/>\n<meta property=\"og:site_name\" content=\"Curiance Biotech\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-06T06:41:33+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/BALVERSA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"761\" \/>\n\t<meta property=\"og:image:height\" content=\"650\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?product=4906\",\"url\":\"https:\\\/\\\/cbmeds.in\\\/?product=4906\",\"name\":\"BALVERSA 3MG \\\/4MG \\\/5MG TABLET (ERDAFITINIB) - Curiance Biotech\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?product=4906#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?product=4906#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cbmeds.in\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/BALVERSA.jpg\",\"datePublished\":\"2025-06-06T06:37:32+00:00\",\"dateModified\":\"2025-06-06T06:41:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?product=4906#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cbmeds.in\\\/?product=4906\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?product=4906#primaryimage\",\"url\":\"https:\\\/\\\/cbmeds.in\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/BALVERSA.jpg\",\"contentUrl\":\"https:\\\/\\\/cbmeds.in\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/BALVERSA.jpg\",\"width\":761,\"height\":650},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/?product=4906#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cbmeds.in\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shop\",\"item\":\"https:\\\/\\\/cbmeds.in\\\/?page_id=13\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"BALVERSA 3MG \\\/4MG \\\/5MG TABLET (ERDAFITINIB)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#website\",\"url\":\"https:\\\/\\\/cbmeds.in\\\/\",\"name\":\"cbmeds.in\",\"description\":\"Tomorrow&#039;s Medicine Today\",\"publisher\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#organization\"},\"alternateName\":\"Curiance Biotech\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cbmeds.in\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#organization\",\"name\":\"CB Meds\",\"url\":\"https:\\\/\\\/cbmeds.in\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cbmeds.in\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Logo-1-1-1.png\",\"contentUrl\":\"https:\\\/\\\/cbmeds.in\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Logo-1-1-1.png\",\"width\":640,\"height\":640,\"caption\":\"CB Meds\"},\"image\":{\"@id\":\"https:\\\/\\\/cbmeds.in\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BALVERSA 3MG \/4MG \/5MG TABLET (ERDAFITINIB) - Curiance Biotech","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cbmeds.in\/?product=4906","og_locale":"en_US","og_type":"article","og_title":"BALVERSA 3MG \/4MG \/5MG TABLET (ERDAFITINIB) - Curiance Biotech","og_description":"\ud83d\udccc Key Details    Brand Name: Balversa    Generic Name (Salt): Erdafitinib    Manufacturer: Janssen Pharmaceuticals, Inc.    Formulation: Oral tablets    Available Strengths: 3 mg, 4 mg, and 5 mg    Indication: Treatment of adults with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 genetic alterations, whose disease has progressed on or after at least one line of prior systemic therapy","og_url":"https:\/\/cbmeds.in\/?product=4906","og_site_name":"Curiance Biotech","article_modified_time":"2025-06-06T06:41:33+00:00","og_image":[{"width":761,"height":650,"url":"http:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/BALVERSA.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cbmeds.in\/?product=4906","url":"https:\/\/cbmeds.in\/?product=4906","name":"BALVERSA 3MG \/4MG \/5MG TABLET (ERDAFITINIB) - Curiance Biotech","isPartOf":{"@id":"https:\/\/cbmeds.in\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cbmeds.in\/?product=4906#primaryimage"},"image":{"@id":"https:\/\/cbmeds.in\/?product=4906#primaryimage"},"thumbnailUrl":"https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/BALVERSA.jpg","datePublished":"2025-06-06T06:37:32+00:00","dateModified":"2025-06-06T06:41:33+00:00","breadcrumb":{"@id":"https:\/\/cbmeds.in\/?product=4906#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cbmeds.in\/?product=4906"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cbmeds.in\/?product=4906#primaryimage","url":"https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/BALVERSA.jpg","contentUrl":"https:\/\/cbmeds.in\/wp-content\/uploads\/2025\/06\/BALVERSA.jpg","width":761,"height":650},{"@type":"BreadcrumbList","@id":"https:\/\/cbmeds.in\/?product=4906#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cbmeds.in\/"},{"@type":"ListItem","position":2,"name":"Shop","item":"https:\/\/cbmeds.in\/?page_id=13"},{"@type":"ListItem","position":3,"name":"BALVERSA 3MG \/4MG \/5MG TABLET (ERDAFITINIB)"}]},{"@type":"WebSite","@id":"https:\/\/cbmeds.in\/#website","url":"https:\/\/cbmeds.in\/","name":"cbmeds.in","description":"Tomorrow&#039;s Medicine Today","publisher":{"@id":"https:\/\/cbmeds.in\/#organization"},"alternateName":"Curiance Biotech","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cbmeds.in\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cbmeds.in\/#organization","name":"CB Meds","url":"https:\/\/cbmeds.in\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cbmeds.in\/#\/schema\/logo\/image\/","url":"https:\/\/cbmeds.in\/wp-content\/uploads\/2023\/09\/Logo-1-1-1.png","contentUrl":"https:\/\/cbmeds.in\/wp-content\/uploads\/2023\/09\/Logo-1-1-1.png","width":640,"height":640,"caption":"CB Meds"},"image":{"@id":"https:\/\/cbmeds.in\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/cbmeds.in\/index.php?rest_route=\/wp\/v2\/product\/4906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cbmeds.in\/index.php?rest_route=\/wp\/v2\/product"}],"about":[{"href":"https:\/\/cbmeds.in\/index.php?rest_route=\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/cbmeds.in\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4906"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cbmeds.in\/index.php?rest_route=\/wp\/v2\/media\/4907"}],"wp:attachment":[{"href":"https:\/\/cbmeds.in\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4906"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/cbmeds.in\/index.php?rest_route=%2Fwp%2Fv2%2Fproduct_brand&post=4906"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/cbmeds.in\/index.php?rest_route=%2Fwp%2Fv2%2Fproduct_cat&post=4906"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/cbmeds.in\/index.php?rest_route=%2Fwp%2Fv2%2Fproduct_tag&post=4906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}